Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use

AIDS Patient Care and STDs

Volumn 19, Issue 2, 2005, Pages 67-69

  Gallego, Oscar ^a   De Mendoza, Carmen ^a   Corral, Angélica ^a   Barrios, Ana ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; TIPRANAVIR; VIRUS RNA;

ANTIVIRAL ACTIVITY; CROSS RESISTANCE; DRUG EFFICACY; DRUG RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LONG TERM CARE; LYMPHOCYTE COUNT; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE;

DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; PYRIDINES; PYRONES; RITONAVIR;

EID: 14344256850     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.67     Document Type: Letter

References (14)

1. Barreiro P, Camino N, de Mendoza C, et al. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. Int J Antimicrob Agents 2002;20:438-443.
2. Burger D, Hugen P, Aarnoutse R, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir+ritonavir combinations: Pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001;26:218-224.
3. De Mendoza C, Martín-Carbonero L, Barreiro P, Soriano V. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002;3:304-309.
4. Valer L, De Mendoza C, Gonzalez de Requena D, et al. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. AIDS 2002;16:1964-1966.
5. Valer L, González de Requena D, de Mendoza C, Martin-Carbonero L, González-Lahoz J, Soriano V. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STDS 2004;18:1-6.
6. Kashman Y, Gustafson K, Fuller R, et al. The calanolides, a novel HIV inhibitor class of coumarin derivates from the tropical rainforest tree Calophyllum lanigerum. J Med Chem 1992;35:2735-2743.
7. Thaisrivongs S, Tomich P, Watenpaugh K, et al. Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994;37:3200-3204.
8. Back N, Van Wijk A, Remmerswaal D, et al. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000;14:100-101.
9. Larder B, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000;14:1943-1948.
10. Squires K, McCallister S, Lazzarin A, et al. Tipranavir/ritonavir (TPV/r) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: Correlation of baseline genotype and antiviral activity in BI 1182.52. Antiviral Ther 2003;8(suppl):412.
11. McCallister S, Kohlbrenner V, Squires K, et al. Characterization of the impact of genotype, phenotype, and inhibitory quotient on antiviral activity of tipranavir in highly treatment-experienced patients. Antiviral Ther 2003;8(suppl):15.
12. Postel N, Wolf E, Ruemmelein N, Buchberger A, Jaegel-Gudes E, Jaeger H. UPAMs are responsible for lopinavir/ritonavir-based HAART failure - Analysis of 79 patients based on genotyping [Abstract 3.4/9]. 9th European AIDS Conference, Warsaw, Poland: October 25-29 2003.
13. Kempf D, Isaacson J, King M, et al. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from PI-experienced patients. J Virol 2001;75:7462-7469.
14. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neuronal networks. J Infect Dis 2003;188:653-660.